.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
EMPEROR-Preserved extended the role of SGLT2 inhibition into heart failure with preserved ejection fraction (HFpEF). In more than 5,900 patients with symptomatic heart failure and an ejection fraction above 40%, empagliflozin significantly reduced the composite of cardiovascular death or hospitalization for heart failure compared with placebo. The effect was driven mainly by a reduction in heart-failure hospitalizations, while the benefit was consistent across a wide range of ejection fractions. The trial is important for internists because HFpEF is common, heterogeneous and closely linked to hypertension, obesity, diabetes, chronic kidney disease and atrial fibrillation. Rather than focusing on a single filling-pressure or ejection-fraction number, management increasingly requires attention to the patient's whole cardiometabolic phenotype. SGLT2 inhibitors provide an evidence-based treatment option with benefits extending beyond glucose lowering. Practical implementation still requires attention to volume status, renal function, genital infections and sick-day management. The broader lesson for general medicine is that modern heart-failure therapy is increasingly disease modifying across phenotypes, but treatment remains most effective when comorbidities are recognized and addressed systematically.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
EMPEROR-Preserved extended the role of SGLT2 inhibition into heart failure with preserved ejection fraction (HFpEF). In more than 5,900 patients with symptomatic heart failure and an ejection fraction above 40%, empagliflozin significantly reduced the composite of cardiovascular death or hospitalization for heart failure compared with placebo. The effect was driven mainly by a reduction in heart-failure hospitalizations, while the benefit was consistent across a wide range of ejection fractions. The trial is important for internists because HFpEF is common, heterogeneous and closely linked to hypertension, obesity, diabetes, chronic kidney disease and atrial fibrillation. Rather than focusing on a single filling-pressure or ejection-fraction number, management increasingly requires attention to the patient's whole cardiometabolic phenotype. SGLT2 inhibitors provide an evidence-based treatment option with benefits extending beyond glucose lowering. Practical implementation still requires attention to volume status, renal function, genital infections and sick-day management. The broader lesson for general medicine is that modern heart-failure therapy is increasingly disease modifying across phenotypes, but treatment remains most effective when comorbidities are recognized and addressed systematically.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
4 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
